RLMD 8-K: SEC filing
Relmada Therapeutics
Filed with the SEC on · accession 0001213900-26-118933
RLMD filed a 8-K (current report) with the SEC on Nov 12, 2026. Relmada Therapeutics issued a press release reporting preliminary unaudited financial results for the third quarter ended September 30, 2026, along with a corporate update, and updated its corporate presentation.
Summary of the filing
Relmada Therapeutics issued a press release reporting preliminary unaudited financial results for the third quarter ended September 30, 2026, along with a corporate update, and updated its corporate presentation. The company also announced a conference call and webcast to discuss the results.
Key details
✦ Ask GOAX AI about this filing — what it means for RLMD, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for RLMD?
Click hereFrequently asked questions
What did RLMD file with the SEC on Nov 12, 2026?
RLMD filed a 8-K (SEC filing). Relmada Therapeutics issued a press release reporting preliminary unaudited financial results for the third quarter ended September 30, 2026, along with a corporate update, and updated its corporate presentation. The company also announced a conference call and webcast to discuss the results.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other RLMD SEC filings
Get alerts when RLMD files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days